Johnson & Johnson Offers $5.5 Billion Settlement in Talc Lawsuits. Here’s What Women Should Know

Mother gently caring for her baby's skin during a diaper change at home

On July 27, 2026, Johnson & Johnson announced a proposed resolution of approximately 76,000 remaining U.S. ovarian cancer claims involving its talc products.

In its announcement, the company stated a $5.5 billion commitment, subject to conditions including express participation covering at least 95% of the remaining claims.

J&J continues to deny that its talc products cause cancer. Lawyers representing the plaintiffs described the proposed settlement as uncapped.

Illustrative photo by Nataliya Vaitkevich on Pexels

Editor’s Note

This article summarizes current legal developments and publicly available scientific evidence. The proposed settlement does not represent an admission of liability by Johnson & Johnson, and scientific research on talc and ovarian cancer remains under discussion.

Why Is Johnson & Johnson Paying Billions?

At first glance, it may sound like Johnson & Johnson has admitted its baby powder caused cancer.

That isn’t what happened.

The company has consistently maintained that its talc products are safe, asbestos-free, and backed by decades of scientific testing. Even while announcing the proposed settlement, J&J repeated that the allegations against it are “without merit.”

According to Erik Haas, Vice President of Litigation at Johnson & Johnson, resolving the lawsuits allows the company to move forward and focus on developing medicines and medical technologies instead of continuing years of courtroom battles.

For many large companies, settlements are sometimes viewed as a practical business decision. Continuing thousands of individual trials across different states can take years, cost billions of dollars in legal fees, and produce unpredictable verdicts.

That doesn’t automatically mean the company agrees with the claims being made against it.

How Did This Controversy Begin?

The controversy dates back more than 15 years.

Around 2009, women across the United States began filing lawsuits claiming they had developed ovarian cancer after regularly using Johnson’s Baby Powder or other talc-based products for feminine hygiene over many years.

Most of these women said they had applied the powder around the genital area, believing it helped them stay dry and comfortable.

Their lawsuits raised two major arguments.

The first claim was that tiny talc particles could travel through the female reproductive tract, eventually reaching the ovaries and contributing to long-term inflammation that might increase cancer risk.

The second claim received even more attention.

Some plaintiffs argued that certain talc products were contaminated with asbestos, a naturally occurring mineral known to cause cancer. Because talc and asbestos can sometimes be found close together underground, critics argued that contamination could occur during mining unless carefully prevented.

In October 2019, J&J voluntarily recalled one U.S. lot of Johnson’s Baby Powder after FDA testing detected chrysotile asbestos in a sample. The agency also reported that a sample from a different lot tested negative.

Johnson & Johnson has repeatedly rejected these claims, saying its cosmetic talc was carefully tested and did not contain asbestos.

Why Did So Many Women Decide to Sue?

As more women learned about the lawsuits, thousands began asking the same question:

“Could my cancer have been linked to something I used almost every day?”

That question led to one of the largest product liability cases in U.S. history.

Some juries awarded substantial compensation to women and their families. Other courts ruled in Johnson & Johnson’s favor or reduced earlier verdicts on appeal.

This is one reason the story has often seemed confusing.

Depending on which court case people read about, the headlines could look completely different.

One jury might conclude there was enough evidence to support a plaintiff’s claim, while another court could determine that the available scientific evidence was not strong enough to prove that talc caused a specific woman’s cancer.

Rather than producing one clear legal answer, the litigation created years of conflicting outcomes.

The Science Turned Out to Be More Complicated Than Many Headlines Suggested

In July 2024, the International Agency for Research on Cancer (IARC), part of the World Health Organization, classified talc as “probably carcinogenic to humans” (Group 2A). The assessment combined limited human evidence for ovarian cancer with sufficient evidence in animals and strong mechanistic evidence.

This classification identifies a cancer hazard. It does not quantify an individual user’s risk or establish that a particular product caused a specific person’s cancer.

Talc containing asbestos is covered by IARC’s separate Group 1 classification for asbestos, which is carcinogenic to humans.

Why Johnson & Johnson Stopped Selling Talc Baby Powder

One of the biggest misconceptions about this case is that Johnson & Johnson removed its talc-based baby powder from the market because it admitted the product was dangerous.

That isn’t what the company has said.

In 2020, J&J stopped selling talc-based Johnson’s Baby Powder in the United States and Canada, citing declining demand and what it described as widespread “misinformation” surrounding the product. The company continued to insist that decades of testing supported the safety of its cosmetic talc.

In August 2022, the company announced a global transition to cornstarch-based baby powder, with talc-based Johnson’s Baby Powder being discontinued worldwide in 2023.

For many consumers, this raised an obvious question:

“If the product was safe, why replace it?”

Johnson & Johnson says the decision reflected changing consumer preferences and years of legal disputes rather than concerns about product safety. Critics, however, argue that the move acknowledged growing public concern and reduced future legal risks.

Those different interpretations remain part of the ongoing debate.

As thousands of lawsuits continued to grow, Johnson & Johnson looked for a way to resolve them all at once instead of fighting individual cases across the country.

The company created a separate subsidiary that assumed responsibility for the talc-related claims and then placed that subsidiary into bankruptcy.

This legal strategy became widely known as the “Texas Two-Step.”

The idea was to use bankruptcy proceedings to negotiate one large settlement that would cover both current and future claims.

However, U.S. courts rejected that approach multiple times.

Earlier bankruptcy attempts failed over findings that the subsidiary was not in sufficient financial distress. The third attempt, involving Red River Talc, was rejected on March 31, 2025, for reasons including irregularities in claimant voting and impermissible protections for companies outside the bankruptcy without affected claimants’ consent.

The cases therefore did not all fail for the same reason.

After those bankruptcy efforts failed, settlement negotiations resumed directly between the company and lawyers representing thousands of women.

Why Did Johnson & Johnson Choose to Settle Now?

Interestingly, the proposed settlement comes after several legal developments that appeared to strengthen Johnson & Johnson’s position.

Only days before the announcement, a federal judge questioned whether expert witnesses could reliably prove that talcum powder specifically caused ovarian cancer in individual women. The judge did not dismiss the lawsuits but signaled that plaintiffs would need stronger scientific evidence to continue many of the cases.

At the same time, Johnson & Johnson had won several recent trials, while other verdicts in favor of plaintiffs had been reduced or overturned on appeal.

Lawyers representing the plaintiffs described the proposed agreement as a route to compensation after more than a decade of litigation.

What Does This Mean for Consumers Today?

If you’ve used Johnson’s Baby Powder in the past, headlines like these can understandably feel alarming.

However, it’s important to keep the situation in perspective.

First, the current settlement does not mean Johnson & Johnson has admitted its products caused cancer. The company continues to deny those allegations and says the agreement is intended to end years of costly litigation.

Second, today’s Johnson’s Baby Powder is not the same product that became the focus of these lawsuits.

The company no longer markets a talc-based version globally, having replaced it with a cornstarch-based formula.

Finally, ovarian cancer remains a complex disease with many known risk factors, including age, inherited genetic mutations such as BRCA1 and BRCA2, reproductive history, obesity, hormone exposure, and family history.

Scientists continue to study whether long-term genital use of talcum powder plays a role for some women, but the evidence has not produced one universally accepted answer.

That scientific uncertainty is one reason these lawsuits have remained controversial for so many years.

What Happens Next

The proposal announced in July 2026 was conditional on participation requirements and other conditions being met. It addresses existing ovarian cancer claims; future lawsuits remain outside its scope.

Under the terms announced by J&J, an initial payment of no more than $3 billion was planned for 2027, with no additional payments due before 2028.

Which part of the talc story would you like to understand more clearly?

Share your questions about the settlement or the scientific evidence.

Leave a comment below to help guide our future coverage.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top